Urothelial Carcinoma

BRAVO Study: Blue Light Cystoscopy Reduces Recurrence in Patients With NMIBC

Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.

Latest News

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.

Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025

The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.

Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.

Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.

Balancing EV/Pembro and Gem/Cis-Nivo: Selecting the Right 1L Therapy for Node-Only Disease

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma Diagnostics

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Conference Coverage

ADAPT-BLADDER Cohort 4: A Phase 1/2 Trial of Durvalumab Plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive NMIBC

Noah Hahn, MDUrothelial Carcinoma | February 24, 2025

Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.

Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025

Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.

ASCO GU Prostate Updates: TALAPRO-2 and Other Considerations

Karine Tawagi, MDProstate Cancer | February 24, 2025

Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.

ASCO GU Bladder Updates: EV-302, CheckMate 274, and More

Karine Tawagi, MDUrothelial Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.

ASCO GU Kidney Updates: Triplets, KIM-1, and More

Karine Tawagi, MDRenal Cell Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.

EV-302: Updated Analysis From the Phase 3 Global Study

Guru P. Sonpavde, MDUrothelial Carcinoma | February 24, 2025

Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.